The success of NIPRO’s biosimilar product, launched in late 2023, has exceeded expectations and gained significant market ...

Sanofi and Johnson & Johnson’s E. coli vaccine candidate failed to prevent invasive E. coli disease effectively.

Aversa Fentanyl holds the potential to become the world’s first abuse-deterrent opioid patch.

New service ensures rapid delivery of small volume clinical trial materials, solving a critical bottleneck in drug ...

Will significantly enhance service to researchers and institutions across China.

The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to CUSP06, a Cadherin-6 targeting ...

Novartis has agreed to acquire Anthos Therapeutics, Inc., a Boston-based, privately held, clinical-stage biopharmaceutical ...

Alcami Corporation, a contract development and manufacturing organization (CDMO), has appointed pharmaceutical industry ...

AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha therapies, is expanding the scope and ...

Bryan O’Donnell, Head of Quality at Gaelic Laboratories, explains how to navigate GMP challenges to ensure your company ...

Biosimilars sales were $201.5 million, up 7% driven by Benepali, with sales of $125 million, up 16%. LEQEMBI global in-market sales in the quarter were approximately $87 million, including U.S.

The project is set to become the largest GMP temperature-controlled facility fully dedicated to the life sciences sector in ...